SCHEMBL1855490

SCHEMBL1855490

COC(=O)Cc1n[c]ncc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
GAA P10253 3/20 0.37
MAPT P10636 2/20 0.36
HSP90AB1 P08238 1/20 0.36
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
HSD17B10 Q99714 2/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 4/20 0.32
PDGFRB P09619 1/20 0.32
FGFR1 P11362 1/20 0.32
PDGFRA P16234 1/20 0.32
FLT1 P17948 1/20 0.32
FGFR3 P22607 1/20 0.32
KDR P35968 1/20 0.32
KDM4E B2RXH2 3/20 0.31
USP2 O75604 1/20 0.31
GFER P55789 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15539926 0.79 HTT (0.38) HTT
SCHEMBL1855491 0.77 HSP90AB1 (0.36) SMN1; SMN2GAAMAPTHSP90AB1CYP4F2
SCHEMBL15416248 0.73 KDM4E (0.31) KDM4ELMNA
SCHEMBL21373807 0.69 ALDH1A1 (0.40) SMN1; SMN2GAAMAPTHSP90AB1NPC1
SCHEMBL3587690 0.67 SMN1; SMN2 (0.46) SMN1; SMN2GAAMAPTHSP90AB1CYP4F2
SCHEMBL4810406 0.66 GAA (0.44) SMN1; SMN2GAAMAPTHSP90AB1CYP4F2
SCHEMBL21862560 0.66 GAA (0.44) SMN1; SMN2GAAMAPTHSP90AB1CYP4F2
Hydrochloric Acid SCHEMBL3587687 0.66 SMN1; SMN2 (0.45) SMN1; SMN2GAAMAPTHSP90AB1CYP4F2
SCHEMBL7882626 0.64 MAPT (0.46) SMN1; SMN2GAAMAPTNPC1RAB9A
SCHEMBL31648323 0.64 AGBL2 (0.70) SMN1; SMN2GAAMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA SMN1; SMN2 1521/4885GAA 1760/4885MAPT 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.